Glofitamab
- Generic Name
- Glofitamab
- Brand Names
- Columvi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2229047-91-8
- Unique Ingredient Identifier
- 06P3KLK2J8
- Background
Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively. It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.
...
- Indication
Glofitamab is indicated in Canada for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from follicular lymphoma, or primary mediastinal B-cell lymphoma (PMBCL), who have received two or more lines of systemic therapy and are ineligible to receive or cannot receive CAR-T c...
- Associated Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B Cell Lymphoma (PMBCL), Refractory Diffuse Large B Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Associated Therapies
- -
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
- Conditions
- Interventions
- First Posted Date
- 2018-03-16
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 172
- Registration Number
- NCT03467373
- Locations
- 🇩🇰
Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT, København Ø, Denmark
🇺🇸University of Alabama Medical Center, Birmingham, Alabama, United States
🇺🇸Fox Chase-Temple Cancer Center, Philadelphia, Pennsylvania, United States
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-03-09
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 860
- Registration Number
- NCT03075696
- Locations
- 🇵🇱
Uniwersytecki Szpital Kliniczny; Klinika Hematologii, Terapii Komórkowych i Chorób Wewn?trznych, Wroc?aw, Poland
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Ingalls Memorial Hospital, Harvey, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.